Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: IDV Haplotype Caller Validation Set

PROVIDER: PRJNA978584 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24796009_1.fastq.gz	Fastqsanger.gz
	SRR24796010_1.fastq.gz	Fastqsanger.gz
	SRR24796011_1.fastq.gz	Fastqsanger.gz
	SRR24796012_1.fastq.gz	Fastqsanger.gz
	SRR24796013_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 7

Similar Datasets

Homo sapiens

Project description:Human hepatocellular carcinomas validation set

| PRJNA101845 | ENA

Project description:GenomeTrakr WGS Validation Strain Set

| PRJNA1101017 | ENA

Homo sapiens

Project description:Human meningioma fixed tumour tissue: validation set

| PRJNA122829 | ENA

HLA-DRB1*15:01 and HLA-DRB5*01:01 peptidomes

Project description:HLA-DR15 is a haplotype associated with multiple sclerosis. It contains the two DRB* genes DRB1*1501 (DR2b) and DRB5*0101 (DR2a). The reported anchor motif of the corresponding HLA-DR molecules was determined years ago based on a small number of peptide ligands and binding assays. DR2a could display a set of peptides complementary to that presented by DR2b or, alternatively, a similar peptide repertoire but recognized in a different manner by T cells. It is known that DR2a and DR2b share some peptide ligands, although the degree of similarity of their associated peptidomes remains unclear. In addition, the contribution of each molecule to the global peptide repertoire presented by the HLA-DR15 haplotype has not been evaluated. We used mass spectrometry to analyze the peptide pools bound to DR2a and DR2b, identifying 169 and 555 unique peptide ligands of DR2a and DR2b, respectively. The analysis of these sets of peptides allowed the refinement of the corresponding binding motifs revealing novel anchor residues that had been overlooked in previous analyses. Moreover, the number of shared ligands between both molecules was low, indicating that DR2a and DR2b present complementary peptide repertoires to T cells. Finally, our analysis suggests that, quantitatively, both molecules contribute to the peptide repertoire presented by cells expressing the HLA-DR15 haplotype.

2017-10-10 | PXD006534 | Pride

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma

Project description:Phenotypic and genomic characterization of Early Stage Breast Carcinoma using Training set (n=109) Validation set (n=105) of SNP6 arrays

2014-02-18 | GSE48064 | GEO

Project description:Enriched metagenome sequencing for CARPDM probe set validation

| PRJNA1093140 | ENA

The second Validation set of the 95GC in 2013.

Project description:The second Validation set of the 95GC in 2013.

| PRJNA978565 | ENA

Homo sapiens

Project description:Gene expression profiles of human hepatocellular carcinoma (validation set)

| PRJNA194395 | ENA

Normalized expression (validation set) - samples

Project description:Normalized expression data; validation set

| EGAD00010000211 | EGA

A robust circulating microRNA signature for diagnosis and early detection in pancreatobiliary cancer

Project description:Purpose: Oncologists for pancreatobiliary cancer (PBca) demand a new circulating biomarker superior to carbohydrate antigen 19-9 (CA19-9). This study aimed to identify the serum microRNA signature composed of reproducible and disease-related microRNAs with clinical bioinformatics. Methods: This multicenter study enrolled patients with treatment-naïve PBca and healthy participants. Optimized serum processing condition was evaluated with t-distributed stochastic neighbor embedding (t-SNE) visualization. The serum microRNA candidates were selected in disease association with Weighted Gene Coexpression Network Analysis (WGCNA). A microRNA signature, combination of multiple serum microRNAs, was examined in exploratory, validation and independent validation set. Biology of the diagnostic miRNAs was evaluated using human pancreatic cancer cells. Results: The 284 (healthy 150, PBca 134) of 827 serum samples were processed within 2hr of time-to serum collection, distributed at the same area of t-SNE map, assigned to exploratory set. The 193 optimized samples were assigned to validation (healthy 50, PBca 47) or independent validation set (healthy 50, PBca 46). Index-1 was a combination of the 5 serum microRNAs having disease-association on WGCNA, showed a sensitivity/specificity >80% and an AUC outperforming CA19-9 in exploratory, validation and independent validation set. The AUC of Index-1 for detecting T1 tumor was superior to CA19-9 (0.856 vs. 0.649, p = 0.038). Human pancreatic cancer cells had intra- and extracellular expression of miR-665, a component of Index-1. Transfection of miR-665 to a human pancreatic cancer cell inhibited cell growth. Conclusions: A serum microRNA signature, Index-1, was useful for detecting PBca, which would improve the early diagnosis of PBca.

2025-01-22 | GSE268524 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data